SCIENTIFIC ADVISORY BOARD

The Company has relationships with a number of scientific and clinical advisors who are leading experts in ion channel biology and chemistry, preclinical studies, drug manufacturing or clinical trials. Our scientific and clinical advisors consult with us regularly on matters relating to our research and development programs; the design and implementation of our clinical trials; market opportunities from a clinical perspective; new technologies relevant to our research and development programs; and a variety of scientific and technical issues.


John Bettis, Ph.D.
Former Vice President, Technical Development, Burroughs Wellcome

Carlo Brugnara, M.D.
Professor of Pathology, Harvard Medical School

Shelley Ching, DVM, Ph.D.
Former International Head, Full Development Programs and Medicines Safety Evaluation, Glaxo Wellcome

John Dillberger, DVM, Ph.D.
Toxicology, Glaxo Wellcome and Triangle Pharmaceuticals

Roy Swaringen, Ph.D.
Formerly Director, Chemical Development, Burroughs Wellcome

Dhirren Thakker, Ph.D.
Professor and Associate Dean, Graduate Education and Scholarship, University of North Carolina at Chapel Hill School of Pharmacy

David R. Williams, Ph.D.
Professor and Chair, Organic Chemistry, Indiana University

Christine Sang, M.D., M.P.H.

Director of Translational Pain Research Program, Brigham and Women’s Hospital

Ian Skidmore, Ph.D.

Former Chairman Worldwide Exploratory Development Committee, Glaxo Wellcome

Cheryl Zimmerman, Ph.D.

Professor of Pharmaceutics, University of Minnesota